Genzyme Reports Solid Financial Results for the First Quarter of 2009
Genzyme Corp. today reported that first-quarter revenue rose to $1.15 billion, compared with $1.10 billion in the same period a year ago, an increase of 4 percent. Including the $66 million impact of unfavorable currency exchange rates, revenue grew 10 percent in the first quarter. Read more ›
Genzyme Further Expands Biomanufacturing Plant in Belgium
Biotechnology company Genzyme announced today it will further expand its high-tech cell culture production facility in Geel, Belgium, with an additional bioreactor of 4000 liter. The investment for this amounts to €46 million euro, and eighty extra jobs will be created at the Geel site. Read more ›
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis
Genzyme Corporation announced today that it has entered into an agreement to acquire the worldwide rights to Campath®/Mabcampath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential treatment for multiple sclerosis (MS). Read more ›